Physician

Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023

Retrieved on: 
Monday, April 1, 2024
Growth, MLSS, Webcast, Telephone, Education, Dental Service Organizations, Operating cost, Hospital, United, CPT, Injection, Pain management, STA, Physician

Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%.

Key Points: 
  • Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%.
  • For the year ended December 31, 2023, international revenue was approximately $4.1 million, a decrease of $724,000 compared to December 31, 2022.
  • Gross profit for the year ended December 31, 2023, was $6.8 million versus $4.9 million for the year ended December 31, 2022.
  • Operating loss for the year ended December 31, 2023, was $7.1 million versus $8.8 million for the year ended December 31, 2022.

Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer

Retrieved on: 
Monday, April 1, 2024
Burn, Brigham Young University, Avita Medical, MDAI, Business administration, Patient, Global strategy, Artificial intelligence, Spectral, Publication, Master of Business Administration, Health Economics, Johnson & Johnson, Allergan, Government, Physician, Medtech

DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer.

Key Points: 
  • DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer.
  • Jeremiah has more than 20 years of medical device marketing experience, including global marketing and business strategy.
  • Mr. Sparks will be responsible for both domestic and international product commercialization.
  • “We are thrilled to have Jeremiah join the company as we move towards commercialization of DeepView,” said Peter M. Carlson, CEO of Spectral AI.

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Retrieved on: 
Monday, April 1, 2024
Drug discovery, Cancer, Patient, CLDN6, Trial of the century, IND, Toxicology, Context, Physician, Food, Pharmaceutical industry

The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with Claudin 6 (CLDN6)-positive gynecologic and testicular cancers.

Key Points: 
  • The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with Claudin 6 (CLDN6)-positive gynecologic and testicular cancers.
  • “Our IND submission for CTIM-76 is a significant milestone for Context,” said Martin Lehr, CEO of Context.
  • The IND application includes extensive manufacturing, preclinical, and toxicology data to support a first-in-human trial.
  • I am incredibly proud of the entire Context team who worked tirelessly to complete this IND submission.

NMDP Cycle Kicks Off Nationwide Cycling Events Giving Hope to Patients in Need of a Blood Stem Cell Transplant

Retrieved on: 
Friday, March 29, 2024
Eclipse, Diagnosis, Sickle cell disease, Bone marrow, Growth, Physician, Patient, Research, Hope, Leukemia, Date, Daily, Falkenberg, NMDP

By raising funds, NMDP Cycle helps more patients access cell therapy treatments for up to 75 different blood cancers, including leukemia, or blood disorders such as sickle cell disease.

Key Points: 
  • By raising funds, NMDP Cycle helps more patients access cell therapy treatments for up to 75 different blood cancers, including leukemia, or blood disorders such as sickle cell disease.
  • "I am alive today because of the selfless act of a blood stem cell donor,” said Bob Falkenberg, founder of the NMDP cycling program.
  • He began cycling to fundraise for NMDP, would stop at transplant centers along the way, inspiring both hospital staff and patients.
  • The organization recently unveiled breakthrough research that will allow more patients with blood cancer or blood disorders to receive life-saving cell therapy.

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 29, 2024
Retina, Chair, Three Months, Biologics license application, Secretome, Disease, Infection, Incidence, Paratriathlon, Inflammation, Patient, Sale, Limbal stem cell, Research, CIRM, Acquisition, Commercial, Eye, Safety, Retinitis pigmentosa, Food, FDA, BLA, Stargardt disease, Physician, Contingency, Protease, Cryptocurrency

ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • “In 2023, we focused on clinical execution, advancing our Phase 2b CHASE trial of KPI-012 for the treatment of PCED.
  • In December 2023 and March 2024, KALA announced private placement financings with an institutional investor, priced at-the-market under Nasdaq rules.
  • Cash Position: As of December 31, 2023, KALA had cash and cash equivalents of $50.9 million, compared to $56.1 million as of September 30, 2023.
  • Operating Loss: For the quarter ended December 31, 2023, loss from operations was $9.6 million, compared to $10.3 million for the same period in 2022.

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Retrieved on: 
Thursday, March 28, 2024
Narcolepsy, Exercise, Somnolence, New Drug Application, Patient, Visual analogue scale, Sale, NDA, G&A, Arimoclomol, Nature, IND, Bank statement, Microsoft Access, Investment, Therapy, Priority review, Corporation, Audit committee, Research, Niemann–Pick disease, Medical science liaison, Sleep disorder, Brain, Trial of the century, Safety, Interim, Food, Sleep, QuickStart, Disease, FY, Acquisition, Emetine, UCD, COL3A1, Celiprolol, Syndrome, FDA, Marketing, Conference call, Conference, EAP, SDX, NPC, Epworth Sleepiness Scale, Idiopathic hypersomnia, Physician, PDUFA, Pharmaceutical industry

CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023. 

Key Points: 
  • ET
    CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023.
  • “We made solid progress on our key priorities in 2023,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra.
  • Overview of Q4 2023 and FY 2023 Financial Results:
    Net revenue for Q4 2023 was $13.2 million, compared to prior year Q4 net revenue of $2.2 million.
  • ET, to discuss its corporate and financial results for Q4 and FY 2023.

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Retrieved on: 
Thursday, March 28, 2024
MEG, Development, Psychiatry, Veteran, Physician, Post-traumatic stress disorder, NSI, Analysis of variance, Patient, UC, RPQ, Jesse Russell, Radiology, Human services, PCS, Concussion, Trial of the century, University, McGill Pain Questionnaire, Brain damage, Pain, ANOVA, Vaccine, PTSD, MPQ, Medical imaging

HOUSTON, TEXAS, March 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the positive results of a clinical study evaluating Nexalin’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, and is further detailed in an abstract co-authored by the United States Department of Veterans Affairs (VA) San Diego Healthcare System, and the Radiology, Psychiatry and Neurosciences Departments of UC San Deigo.

Key Points: 
  • mTBI is a leading cause of sustained physical, cognitive, emotional, and behavioral deficits in veterans and the general public.
  • However, the underlying pathophysiology is not completely understood, and there are few effective treatments for post-concussive symptoms (PCS).
  • The study was conducted as a randomized, double-blind, placebo-controlled clinical trial over an eight-week period, with two groups being examined: an active tACS group and a sham tACS group.
  • Mark White, CEO of Nexalin Technology, stated, "We are encouraged by the results of the clinical study, reinforcing the significant reduction in pain and other persistent symptoms of mild traumatic brain injury among veteran patients.

Study Finds Clinicians Support Consumers as First Reporters of Early Patient Deterioration in Hospital

Retrieved on: 
Thursday, March 28, 2024
Government, RRS, Communication, Patient, Quality, Flinders Medical Centre, Flinders University, Workload, Nursing, Physician, Patient safety, Pharmaceutical industry

OAKBROOK TERRACE, Illinois, March 28, 2024 (GLOBE NEWSWIRE) -- Detection of early patient deterioration in the hospital can lead to timely intervention and improved outcomes.

Key Points: 
  • OAKBROOK TERRACE, Illinois, March 28, 2024 (GLOBE NEWSWIRE) -- Detection of early patient deterioration in the hospital can lead to timely intervention and improved outcomes.
  • Patients themselves, as well as family members and bedside visitors familiar with the patient’s condition can play a critical role in detecting patient deterioration.
  • A new study in the April 2024 issue of The Joint Commission Journal on Quality and Patient Safety (JQPS), investigates clinicians’ views on consumer reporting (by patients, family members or visitors) of early patient deterioration through an established hospital consumer-initiated escalation-of-care (CIEoC) system.
  • Six major themes and subthemes emerged, including:
    Clinicians support consumer reporting and feel consumers are ideally positioned to recognize early deterioration and raise concerns about it.

CLS Americas Announces ROSE Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation

Retrieved on: 
Thursday, March 28, 2024
Diagnosis, Temperature, Urology, Prostate cancer, Patient, Cancer, Prostate, FLA, Urinary incontinence, Erectile dysfunction, CLS, FDA, Physician, Medical imaging

LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that ROSE Urology, LLC , located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients.

Key Points: 
  • LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that ROSE Urology, LLC , located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients.
  • The system is FDA 510(k) cleared for soft tissue ablation in a urology setting.
  • Operating under CLS's Mobile Services Agreement, CLS will provide its FDA 510(k) cleared TRANBERG Laser, consumable accessories, training, and on-site clinical and technical support to ROSE Urology physicians and staff during procedures.
  • Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.

American Oncology Network Announces Attendance and Participation at Leading Community Oncology Conference

Retrieved on: 
Thursday, March 28, 2024
Community, AON, CSSBB, Growth, Doctor of Pharmacy, Health, Partnership, Education, Patient, Knowledge, Cancer, COA, Hope, Matter, Personalized medicine, Community Oncology Alliance, MD, Privacy, Competition, MBA, Confidentiality, Pharmacy, Physician, Medicine, Pharmaceutical industry

FORT MYERS, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC) announced its attendance and panel participation at the annual Community Oncology Alliance (COA) conference from April 4 to April 5 in Orlando, Florida, to further its mission of closing the cancer care gap and ensuring the viability of community oncology.

Key Points: 
  • FORT MYERS, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC) announced its attendance and panel participation at the annual Community Oncology Alliance (COA) conference from April 4 to April 5 in Orlando, Florida, to further its mission of closing the cancer care gap and ensuring the viability of community oncology.
  • Since its inception, AON has provided administrative support and access to critical offerings such as the in-house pharmacy and laboratory services to independent oncology medical practices.
  • The conference brings together today’s healthcare and community oncology leaders for two days of education and networking.
  • We understand the future of healthcare is a collective effort, and the conference provides a platform to foster unity and the exchange of information.